Initiation of ARNi and SGLT2i in Patients With HFrEF - Trial NCT05989503

Timeline & Enrollment

Primary Outcome

Composite outcome (time-to-first event' occurrence during the 6 months of follow-up):

Summary

Heart failure (HF) is a condition in which the heart does not contract (pump) or relax
 well, leading to insufficient perfusion of vital organs. Ankle swelling, fatigue, and
 breathlessness are some of the features of this syndrome. There are different causes for HF
 (e.g., infarct and hypertension) and two distinct types: HFpEF - HF with preserved ejection
 fraction - the heart pumps but does not relax well and HFrEF/HFmrEF - HF with reduced or
 mildly reduced ejection fraction - where the heart does not pump properly.
 
 Patients with HFrEF experience substantially shorter life expectancies compared with people
 in the general population of similar age. Compared to the different available therapeutics
 for HFrEF patients, angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan,
 has shown superiority for improving clinical outcomes. Furthermore, the new recently drug
 sodium-glucose cotransporter 2 inhibitor (SGLT2i) was proven to reduce mortality and
 morbidity on top of well-adapted background therapy.
 
 This work aims to test the safety of ARNi and SGLT2i initiation by comparing a strategy of
 simultaneous initiation of ARNi and SGLT2i versus sequential initiation of a SGLT2i first
 followed by an ARNi.

ICD-10 Classifications